Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $3.4 million.

  • Rhythm Pharmaceuticals' Other Accumulated Expenses fell 9072.74% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 9072.74%. This contributed to the annual value of $37.7 million for FY2024, which is 59693.16% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Other Accumulated Expenses of $3.4 million as of Q3 2025, which was down 9072.74% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Other Accumulated Expenses ranged from a high of $40.0 million in Q2 2025 and a low of $229000.0 during Q1 2021
  • For the 5-year period, Rhythm Pharmaceuticals' Other Accumulated Expenses averaged around $10.4 million, with its median value being $3.4 million (2025).
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Other Accumulated Expenses skyrocketed by 87615.24% in 2024 and then crashed by 9072.74% in 2025.
  • Rhythm Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $800000.0 in 2021, then soared by 202.38% to $2.4 million in 2022, then surged by 123.65% to $5.4 million in 2023, then soared by 596.93% to $37.7 million in 2024, then plummeted by 90.99% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $40.0 million for Q2 2025, and $38.8 million during Q1 2025.